LYEL LYEL
Company Profile ↓Company Overview
LYEL (LYEL) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $36.00K (-41.0% YoY); net profit $-274.45M.
- Trailing 12 Months Year-on-year growth — revenue -41.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -38.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -38.37% |
| 1 Year: | -40.98% |
Stock Price Performance
| 1 Year: | +18.29% |
| 6 Months: | -47.81% |
| 3 Months: | -34.77% |
| 1 Month: | -15.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -38.4% CAGR over 5 years.
- Trading 65.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.12M | 1.07M | 2.44M | 2.63M | 2.75M | 553.00K | 35.74M | 3.00K | 65.00K | 27.00K | 25.00K | 3.00K | 13.00K | 34.00K | 7.00K | 8.00K | 15.00K | 2.00K |
| Operating Income | -102.57M | -36.84M | -55.37M | -62.71M | -49.16M | -68.58M | -37.26M | -66.44M | -62.56M | -65.91M | -59.04M | -55.58M | -51.53M | -50.51M | -57.37M | -47.14M | -37.25M | -44.26M |
| Net Income | -100.66M | -35.72M | -55.04M | -62.59M | -48.88M | -68.14M | -36.32M | -70.25M | -66.96M | -63.89M | -50.85M | -60.67M | -45.81M | -44.58M | -52.20M | -42.68M | -38.85M | -24.15M |
| Diluted EPS | - | - | -3.19 | -1.47 | -0.20 | -0.28 | -0.15 | -0.28 | -0.27 | -0.26 | -0.20 | -0.24 | -3.59 | -3.48 | -3.54 | -2.89 | -2.13 | -1.10 |
| R&D Expense | 97.15M | 24.50M | 41.53M | 46.45M | 31.43M | 35.83M | 43.72M | 41.61M | 44.63M | 47.47M | 43.85M | 43.17M | 40.26M | 39.50M | 43.45M | 34.86M | 28.17M | 36.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 657.00K | 7.76M | 10.65M | 84.68M | 130.00K | 61.00K | 36.00K |
| Operating Income | -102.09M | -211.94M | -214.78M | -187.06M | -247.01M | -358.75M | -269.40M |
| Net Income | -129.38M | -204.47M | -250.22M | -183.12M | -234.63M | -342.99M | -274.45M |
| Diluted EPS | -24.04 | -15.69 | -1.84 | -0.74 | -18.70 | -26.23 | -16.06 |
| R&D Expense | 63.59M | 182.24M | 138.69M | 159.19M | 182.94M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 908.28M | 1.13B | 937.56M | 750.03M | 490.86M | 340.05M |
| Total Equity | 850.00K | -111.11M | -292.53M | 929.79M | 833.25M | 654.95M | 382.82M | 248.20M |
| Cash & Equivalents | - | 96.67M | 140.41M | 293.83M | 123.55M | 145.65M | 105.60M | 60.18M |
| Total Liabilities | - | - | 189.84M | 197.62M | 104.31M | 95.08M | 108.03M | 91.85M |
| Current Liabilities | - | - | 49.28M | 46.74M | 37.03M | 34.52M | 53.79M | 49.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 39.47M | -160.87M | -126.25M | -169.56M | -163.69M | -162.39M | -150.02M |
| Investing Cash Flow | -422.43M | -273.52M | -121.57M | -11.54M | 184.05M | 122.42M | 54.10M |
| Financing Cash Flow | 351.16M | 476.79M | 401.24M | 10.63M | 1.74M | 1.33M | 50.41M |
| Capital Expenditure | -16.05M | -51.48M | -65.50M | -24.28M | -2.69M | -464.00K | -780.00K |
| Free Cash Flow | 23.43M | -212.35M | -191.75M | -193.83M | -166.38M | -162.86M | -150.80M |
| Share Buybacks | 185.00K | 11.81M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -15,538.7% | -2,732.6% | -2,016.7% | -220.9% | -190,006.2% | -588,123.0% | -748,344.4% |
| Net Margin % | -19,692.1% | -2,636.3% | -2,349.5% | -216.2% | -180,486.2% | -562,285.2% | -762,355.6% |
| ROE % | 116.4% | 69.9% | -26.9% | -22.0% | -35.8% | -89.6% | -110.6% |
| ROCE % | - | -24.7% | -19.9% | -20.8% | -34.5% | -82.1% | -92.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LYEL
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWlB6LVpkRDlQOXJIczFod09pQUo5RXlzV3FUd0Joc2oxcmdzMktyYm1kWU5qbVUyWVVUejRJdTY0WGlxMzFVdTl0dl9VSDdMTXhuTE50cWtkTWRxdzJ3QjY4bW5pejFnZEpfRDR5NXNjS2U1bk1lLW5lcXZ3S05nOVFYWG53WHF2SHZmam…
Stifel initiates Lyell Immunopharma stock with buy, $44 target - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPUjRKdUlnM290Y2ZSY3Z1RTlLNXpkNk0yeTdoeWtVUklsb21sYTgzR0h5Q3J6S2VQWS1qdlVmZVlfTndWbEktTk5wZlZ2STNEQk41SDZBR0MtT1lkTFRKdWRjMHZxYWJ0UXIxaS1QT0swWV9abW42UTQ3ZlE0Z1NCVGdHM2kybjhyZ0FRNn…
CAR T-cell cancer therapy developer Lyell to stream Goldman Sachs chat June 8 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPcU93V2lGMVBialZWRC1Wdkt1UGJOMDcydWs1RFN5S2NsSnJkaDQwVEpnS21RV25FS0VKcXB0UW00NmJDOU5JOTJKVG8wbDF3dWFBWEE5ZFJ0WXhFaHVMYkVJdmJXTDRWQ3g1MjZnUjl2MU1HM2p6U3pRR3lBQ2ZESmpEU3J4OUtqTkxKZk…
Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNR2xfM0NZajlWbXlPSll5ckp2ZHNmOHRucm5vR245VlA5MG1nLXdhLTNFRWtheWxWeDNqSGR2N3FVWVQ0MzE2c3pGWTFPNTJqNlVYN3VtLXB0UnMyZDZzdmxqdEZ5c3dRRHhaV3dSSzZmRzc2Q1hVZ2dZU29GNmhZVVgtRzlOOXlnNEk0Zn…
$LYEL stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxObld6Z1hySm00YVlteHdZWFY4Zkhzb1pyM2pIQVNIRmdQYUxwbUw3a2xGZ0ZhVDdqcHp0eEpYSFZsRklha1F3U01ZeWdMenk4ZFk2aHZHV0I1NVJZS2dIWW1JTWJvUV9EZnNyRnNZczdZMEJWVlNGaHpZcUhwR09wVXI3TnoyaU4wT1N4R3…
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) - qz.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPQ3RsY1NGQkNWdVNlRy1CXy1hQTVlVk9NN2c4OHFmLXBubnJVdFJkajV4aVNuVkd0a0xXTmN2Ml9XWHNLZDBvMk5sZS03bjB4Z1hIWlB0cnpVUkFGMDBiVEttQm5wUXJMY0hTdmRoSHozbXhVdGladTl4a25ETUlEamd4NFBnQmZiaGxnVG…
LYEL — Frequently Asked Questions
What is the current share price of LYEL?
As of 2026-08-05 17:25 PDT, LYEL trades at $13.45 on NASDAQ/NYSE. Its 52-week range is $10.57 to $38.60.
What is the P/E ratio of LYEL?
LYEL trades at a trailing price-to-earnings (P/E) ratio of -0.84.
What is the return on equity (ROE) of LYEL?
LYEL has a return on equity (ROE) of -110.57%. Its return on capital employed (ROCE) is -92.69%.
Is LYEL a good stock to buy?
This page provides a data-driven analysis of LYEL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.